Dec 11 (Reuters) - Noxopharm Ltd (NOX) :
- CO'S DARRT-1 CLINICAL STUDY HAS BEEN APPROVED TO MOVE TO ITS FINAL STAGE
- ALL 3 DOSE LEVELS OF VEYONDA IN COMBINATION WITH RADIOTHERAPY WERE WELL TOLERATED , WITHOUT ANY REPORTED SAFETY ISSUES
Source text (http//reut.rs/2G7vORS)
(([email protected];))
News: NOX Noxopharm Says Co's Darrt-1 Clinical Study Has Been Approved To Move To Its Final Stage
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.9¢ | $4.773K | 48.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20574 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 38542 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
